Passage Bio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.45 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 11.10M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Details
| Name | Passage Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 24 |
| Founded | 2017 |
| Ipo Date | 2020-02-28 |
| Ceo | William Chou |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 18.00 |
| Isin | US7027122099 |
| Cusip | 702712209 |
| Cik | 1787297 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. William Chou M.D., Ph.D. | President, Chief Executive Officer and Director |
| Kathleen Borthwick | Senior Vice President, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
Contact
| Address | One Commerce Square, 2005 Market Street, Philadelphia, Pennsylvania 19103, United States |
| Phone | 267 866 0311 |
| Website | https://www.passagebio.com |